Changeflow GovPing Securities & Markets Wave Life Sciences 8-K Reports Q1 2026 Results
Routine Notice Added Final

Wave Life Sciences 8-K Reports Q1 2026 Results

Favicon for www.sec.gov SEC EDGAR - Form 8-K Filings
Published
Detected
Email

Summary

Wave Life Sciences Ltd. filed a Form 8-K current report with the SEC on April 28, 2026, disclosing results of operations and financial condition under Item 2.02, along with a Regulation FD disclosure under Item 7.01 and financial statements and exhibits under Item 9.01. The filing includes two exhibits (EX-99.1 and EX-99.2) and was accepted at 07:34:43 Eastern Time. Wave Life Sciences is a pharmaceutical preparations company (SIC 2834) incorporated under the laws of a foreign jurisdiction, with its primary business address in Cambridge, Massachusetts and operational presence in Singapore.

Published by SEC on sec.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors SEC EDGAR - Form 8-K Filings for new securities & markets regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.

View original document View source feed page
Notice an inaccuracy or want this record removed? Email corrections@changeflow.com . We respond within 48 hours and honor reasonable requests. See our editorial standards .

What changed

Wave Life Sciences Ltd. submitted a Form 8-K current report to the SEC disclosing material information regarding its results of operations and financial condition. The filing covers three disclosure items: Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). Two exhibits accompany the filing (EX-99.1 and EX-99.2).

Public companies, investors, and market analysts should note that this 8-K filing represents Wave Life Sciences' disclosure of quarterly operational results to the SEC under Regulation FD, which requires simultaneous public dissemination of material information. The filing provides financial context for a clinical-stage pharmaceutical company focused on RNA-based therapeutics.

Archived snapshot

Apr 28, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Filing Detail

  • SEC Home »
  • Company Search »
  • Current Page Form 8-K - Current report: SEC Accession No. 0001193125-26-183563 Filing Date 2026-04-28 Accepted 2026-04-28 07:34:43 Documents 65 Period of Report 2026-04-28 Items Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files
Seq Description Document Type Size
1 8-K d135689d8k.htm iXBRL 8-K 26634
2 EX-99.1 d135689dex991.htm EX-99.1 91087
3 EX-99.2 d135689dex992.htm EX-99.2 55789
7 GRAPHIC g135689ex99_1p10g1.jpg GRAPHIC 267084
8 GRAPHIC g135689ex99_1p11g1.jpg GRAPHIC 208773
9 GRAPHIC g135689ex99_1p12g1.jpg GRAPHIC 161482
10 GRAPHIC g135689ex99_1p13g1.jpg GRAPHIC 275907
11 GRAPHIC g135689ex99_1p14g1.jpg GRAPHIC 238312
12 GRAPHIC g135689ex99_1p15g1.jpg GRAPHIC 269766
13 GRAPHIC g135689ex99_1p16g1.jpg GRAPHIC 279313
14 GRAPHIC g135689ex99_1p17g1.jpg GRAPHIC 213478
15 GRAPHIC g135689ex99_1p18g1.jpg GRAPHIC 250414
16 GRAPHIC g135689ex99_1p19g1.jpg GRAPHIC 226892
17 GRAPHIC g135689ex99_1p20g1.jpg GRAPHIC 278744
18 GRAPHIC g135689ex99_1p21g1.jpg GRAPHIC 289021
19 GRAPHIC g135689ex99_1p22g1.jpg GRAPHIC 313203
20 GRAPHIC g135689ex99_1p23g1.jpg GRAPHIC 286646
21 GRAPHIC g135689ex99_1p24g1.jpg GRAPHIC 294797
22 GRAPHIC g135689ex99_1p25g1.jpg GRAPHIC 240808
23 GRAPHIC g135689ex99_1p26g1.jpg GRAPHIC 219519
24 GRAPHIC g135689ex99_1p27g1.jpg GRAPHIC 141070
25 GRAPHIC g135689ex99_1p28g1.jpg GRAPHIC 169925
26 GRAPHIC g135689ex99_1p29g1.jpg GRAPHIC 296995
27 GRAPHIC g135689ex99_1p2g1.jpg GRAPHIC 371440
28 GRAPHIC g135689ex99_1p30g1.jpg GRAPHIC 267955
29 GRAPHIC g135689ex99_1p31g1.jpg GRAPHIC 188216
30 GRAPHIC g135689ex99_1p32g1.jpg GRAPHIC 279666
31 GRAPHIC g135689ex99_1p33g1.jpg GRAPHIC 291696
32 GRAPHIC g135689ex99_1p34g1.jpg GRAPHIC 237061
33 GRAPHIC g135689ex99_1p35g1.jpg GRAPHIC 268097
34 GRAPHIC g135689ex99_1p36g1.jpg GRAPHIC 182795
35 GRAPHIC g135689ex99_1p37g1.jpg GRAPHIC 148333
36 GRAPHIC g135689ex99_1p38g1.jpg GRAPHIC 239880
37 GRAPHIC g135689ex99_1p39g1.jpg GRAPHIC 239316
38 GRAPHIC g135689ex99_1p3g1.jpg GRAPHIC 296891
39 GRAPHIC g135689ex99_1p40g1.jpg GRAPHIC 299354
40 GRAPHIC g135689ex99_1p41g1.jpg GRAPHIC 276459
41 GRAPHIC g135689ex99_1p42g1.jpg GRAPHIC 198940
42 GRAPHIC g135689ex99_1p43g1.jpg GRAPHIC 164548
43 GRAPHIC g135689ex99_1p44g1.jpg GRAPHIC 242688
44 GRAPHIC g135689ex99_1p45g1.jpg GRAPHIC 150448
45 GRAPHIC g135689ex99_1p46g1.jpg GRAPHIC 292110
46 GRAPHIC g135689ex99_1p47g1.jpg GRAPHIC 293591
47 GRAPHIC g135689ex99_1p48g1.jpg GRAPHIC 154334
48 GRAPHIC g135689ex99_1p49g1.jpg GRAPHIC 211533
49 GRAPHIC g135689ex99_1p4g1.jpg GRAPHIC 253001
50 GRAPHIC g135689ex99_1p50g1.jpg GRAPHIC 233960
51 GRAPHIC g135689ex99_1p51g1.jpg GRAPHIC 183225
52 GRAPHIC g135689ex99_1p5g1.jpg GRAPHIC 264397
53 GRAPHIC g135689ex99_1p6g1.jpg GRAPHIC 199511
54 GRAPHIC g135689ex99_1p7g1.jpg GRAPHIC 143033
55 GRAPHIC g135689ex99_1p8g1.jpg GRAPHIC 307884
56 GRAPHIC g135689ex99_1p9g1.jpg GRAPHIC 240921
57 GRAPHIC g135689ex99_2p1g1.jpg GRAPHIC 299953
58 GRAPHIC g135689g0428082216300.jpg GRAPHIC 5867
Complete submission text file 0001193125-26-183563.txt 17340277

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA wve-20260428.xsd EX-101.SCH 3201
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE wve-20260428_lab.xml EX-101.LAB 17924
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE wve-20260428_pre.xml EX-101.PRE 11252
69 EXTRACTED XBRL INSTANCE DOCUMENT d135689d8k_htm.xml XML 3653
Mailing Address 733 CONCORD AVENUE CAMBRIDGE MA 02138 Business Address 7 STRAITS VIEW #12-00, MARINA ONE EAST TOWER SINGAPORE U0 018936 617-949-2900 Wave Life Sciences Ltd. (Filer) CIK: 0001631574 (see all company filings) EIN.: 000000000 State of Incorp.: U0 Fiscal Year End: 1231

SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mentioned entities

Securities and Exchange Commission

Parties

Wave Life Sciences Ltd.

Related changes

Favicon for www.sec.gov Kiniksa Pharmaceuticals Reports Q1 2026 Financial Results
Routine Apr 28, 2026 • SEC EDGAR - Form 8-K Filings • Securities & Markets
Favicon for changeflow.com Semrush Holdings 8-K: Adobe Merger Completed, NYSE Delisting Effective April 28, 2026
Routine Apr 28, 2026 • EDGAR: Delisting Notices (8-K 3.01) • Securities & Markets
Favicon for www.sec.gov SEC Extends DreamFunded Marketplace Decision to July 27, 2026
Routine Apr 28, 2026 • SEC: Commission Opinions & Adjudicatory Orders • Securities & Markets

Get daily alerts for SEC EDGAR - Form 8-K Filings

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

Source

Favicon for www.sec.gov
SEC EDGAR - Form 8-K Filings sec.gov/cgi-bin/browse-edgar?action=getcurrent&type=8-K&owner=include&count=200&output=atom
Securities & Markets

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from SEC.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Press inquiries →

Classification

Agency
SEC
Published
April 28th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Public companies Investors Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
SEC disclosure filings Financial reporting Investor relations
Geographic scope
United States US

Taxonomy

Primary area
Securities
Operational domain
Compliance
Compliance frameworks
SOX
Topics
Healthcare Corporate Governance

Browse Categories

Agriculture & Food Safety 82 Banking & Finance 492 Consumer Protection 124 Courts & Legal 384 Data Privacy & Cybersecurity 144 Defense & National Security 52 Education 62 Energy 135 Environment 167 Government & Legislation 515 Healthcare & Life Sciences 318 Immigration 11 Insurance 88 Labor & Employment 194 Real Estate & Housing 67 Securities & Markets 163 Tax 116 Telecom & Technology 60 Trade & Sanctions 164 Transportation 131

Get alerts for this source

We'll email you when SEC EDGAR - Form 8-K Filings publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!